Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 April 2022 | Story Elsabé Brits
Andre Roodt and Alice Brink
Prof Andreas Roodt and Prof Alice Brink are two of the inventors of the ‘Multinuclear complexes and their preparation patent.

According to the World Health Organisation (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six. The most common cancers are breast, lung, colon, rectum, and prostate cancers. There is a constant need to provide methods to diagnose and treat cancer-related tumours.  Current research strategies focus on eliminating cancer cells with the minimum damage to surrounding healthy cells.

A limitation of current technologies is that they are mostly based on the separate identification of cancer (diagnostic), followed by treatment (therapy) using chemotherapy and/or radiotherapy. To fit both needs at the same time and with similar or identical compounds, the principle of theranostic medicine was identified. This concept employs both diagnosing (by imaging) cancer and delivering therapy (treatment) simultaneously, which has been receiving increased attention internationally.

Collaborating with the University of Zurich
A University of the Free State (UFS) team, together with a team from the University of Zürich, conducted exciting research in this area and filed a patent titled ‘Multinuclear complexes and their preparation’. The patent was granted in South Africa and by the European Patent Office. It is being validated in selected European countries. The patent is pending in the USA, Japan, Hong Kong, and India. The inventors from the UFS are Prof Andreas Roodt, Prof Alice Brink, Dr Pennie Mokolokolo, and Dr Vincent Dumisani Kama. The approach that their technology takes is to enable the synthesis of a multinuclear compound/s, which may contain different pre-selected radioisotopes, to allow both imaging and therapy to the cancer site(s) with one and the same metal-organic complex.

So far, high-yield production of compounds has been successfully innovated, which contain both an imaging (in particular the widely utilised imaging isotope Technetium-99m) and therapeutic (typically the therapeutic isotope Rhenium-186) radioactive isotope(s), optionally carrying an additional cytotoxic agent. (Chemotherapy uses anti-cancer [cytotoxic] drugs to destroy cancer cells.)

Nuclear medicine technologies
In the next phase of the research, a lead compound portfolio of four to five model pharmaceuticals containing these metal nuclides with appropriate directing groups to target cancer sites will be designed and constructed. A number of these entities are known and can be introduced through different techniques. These will then undergo full characterisation and efficacy evaluation in biological models (in vitro), followed by extensive animal and human trials.

The technology will be delivered as a product or service in the way that current nuclear medicine technologies are delivered.

The fact that this product(s) contains both imaging and therapeutic radionuclides or cytotoxic modalities, enables detailed tracking of the pharmaceutical and monitoring of the tumours' response to the therapy. Not directly related to the patent, but an asset to it, is the fact that the incorporation of rhenium with a high atomic number (Z = 75) opens the additional opportunity to utilise the multinuclear compounds also as radiosensitisers. Synergistic effects, enhancing the therapeutic efficacy, can thus be expected in combination with radiotherapy.

The UFS would like to partner with a pharmaceutical company working in the field of nuclear medicine to commercialise this technology. Interested parties can contact Ravini Moodley at MoodleyR5@ufs.ac.za

News Archive

Graduates should use knowledge to ‘re-dream society’
2016-09-19

Description: Spring Graduation 2017 Tags: Spring Graduation 2017

Dr Molapo Qhobela, CEO of the National Research
Foundation was the guest speaker at the
2016 Spring Graduation ceremonies on the
UFS Bloemfontein Campus.
Photo: Johan Roux

“The knowledge you receive, the skills and tools you have acquired, whether they are tools of time management, tenacity or brilliance, are what we as this emerging new society need to re-dream for the type of society we would like see in this country.”

These were the inspiring words of guest speaker Dr Molapo Qhobela to graduates of the University of the Free State (UFS) at the Spring Graduation ceremonies on 15 September 2016 in the Callie Human Centre on the Bloemfontein Campus. Dr Qhobela is the Chief Executive Officer of the National Research Foundation.

A total of 442 degrees, diplomas and certificates were conferred on graduates from six UFS faculties, namely the Faculties of Law, Humanities, Education, Health Sciences, Economic and Management Sciences and Natural and Agricultural Sciences.

Joyous atmosphere befitting a spring ceremony

The spirit at the spring ceremonies was truly inspiring, joyous and heart-warming. The jubilation from the audience as the procession entered the hall demonstrated the exhilaration of graduates and their families. The sense of accomplishment and pride reverberated as the graduates walked across the stage.

Graduates’ hard work and dedication applauded

 “You endured what you had to
endure and you enjoyed what
had to be enjoyed.”

“You have worked incredibly hard and the privilege to walk across the red carpet only goes to those who were prepared to do the work,” Dr Khotso Mokhele, Chancellor of the UFS said.

He applauded graduates for the many hours and sacrifices they had to endure, saying: “You endured what you had to endure and you enjoyed what had to be enjoyed.” Dr Mokhele also mentioned the amazing Gold medal win at the 2016 Olympic Games in Rio de Janeiro of UFS star athlete, Wayde van Niekerk.

Distinctions awarded by the UFS.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept